MXPA99005881A - A medicament container of polymer of cyclic hydrocarbon for storing a liquid medicament - Google Patents

Abstract

The present invention relates to a medicament container for storing a liquid medicament, such as insulin, the container comprising a distal and a proximal end portion and a wall, at least two opposite portions of the wall being of a polymer material. The thickness of the polymer wall portions is between 0.3 mm and 3 mm, and the light transmission through the polymer wall portions at 400 nm are at least 25%. The polymer wall portions are of a material comprising atleast 70%by weight of a copolymer material composed of aliphatic cyclic or bicyclic hydrocarbons with 5 to 7 membered ring or rings and ethylene or propylene, the material having a glass transition temperature above 50°C, and a density of 0.95 g/cm3 or more. The container of the polymer material is substantially inert to the medicament, and furthermore, the container is transparent, whereby it is possible visually to inspect the content of the container to make sure that the medicament is not crystallised or polymerised. Furthermore, the walls of the container provide a good barrier against m-cresol/phenol/benzyl alcohol preservatives and water, respectively. The invention also relates to the use of such medicament container, and a medicament container at least partly filled with medicament.

Description

CONTAINER FOR CYCLICAL HYDROCARBON POLYMER MEDICATION TO STORE A MEDICINE LIQUID DESCRIPTION OF THE INVENTION The present invention relates to a container for medicament, for storing a liquid medicament, to the use of such a container for medicament, and a container for medicament at least partially filled with medicament. 'traditionally, the. containers for medication, for storing liquid medicines and liquid preparations, have been made of glass. For certain medicaments, such as drugs for peroral administration, containers of opaque polyethylenes or polyesters have also been used. Such a polymer container, made of a polyglycolic acid polyester and a terephthalic polyester is, for example, described in US Pat. No. 4,565,851. This container provides a very good barrier against oxygen and other gases, but does not provide a sufficient barrier against preservatives and water.

? SF.z 30574 Medications, such as insulin or growth hormone, are distributed in small containers or ampoules. Such ampules usually comprise between 1.5 and 10 ml of the ready-to-use medicine. These ampoules are stored in reserve, in hospitals or pharmacies and with the user. This means that the shelf life must be long enough. Aqueous solutions or suspensions of medicaments, such as insulin or growth hormones, are usually provided with a preservative, such as phenol and / or benzyl alcohol and / or m-cresol. The addition of preservatives is necessary because terminal sterilization is not possible due to the sensitivity of drugs containing proteins, peptides and / or DNA sequences. Medications in containers that comprise more than one dose, for example, for use in storage or small warehouse systems are at high risk of contamination. Therefore, preservatives are essential ingredients in such medications, particularly in medicines for parenteral administration. Phenol, benzyl alcohol and m-cresol are approved in small amounts for use for parenteral drugs, for example for intramuscular administration. Aqueous solutions or suspensions of medicines that comprise a preservative can be stored in containers for up to 2 years. The article "Interaction between aqueous preservative solutíons and their plastic containers, III" by T.J. McCarthy, Pharm. Wee blad 107 (1972), describes the effects of storing certain aqueous solutions of preservatives in polypropylene (PP) containers colored with white pearlescent pigment and polyvinyl chloride (PVC), respectively, in particular with respect to the loss of conservatives from the solutions. There are no descriptions regarding the storage of aqueous solutions of preservatives in clear containers. In addition, the conclusion of this article is that large quantities of some types of preservatives are lost from solutions stored in PP. PVC, however, seems to provide a good barrier against conservatives. As a consequence of its chlorine content, PVC is not acceptable for use due to environmental contamination. Patent No. JP-A-8-155007 discloses a drug container with improved transparency and heat resistance properties.

Furthermore, the invention relates to a container that has the elution of preservatives. The extract of JP-A-8-155007 does not describe the physical parameters for such improvement. Tarr et al., "Stability and sterility of biosynthetic human insulin stored in plastic syringe for 28 days," American Society of Hospital Phar Acists, vol. 48, pages 2631-34, 1991, describes a similar test for storage of aqueous solutions of phenol, benzyl alcohol and m-cresol, respectively, in polypropylene-polyethylene syringes, in particular with respect to the loss of phenol, benzyl alcohol and m-cresol, respectively, from the solutions. The test covers only 28 days, but from this test it is concluded that the polypropylene-polyethylene syringes can not be used to store drugs comprising phenol and / or benzyl alcohol and / or m-cresol. The ampoules containing insulin or growth hormone are usually stored at refrigerator temperature at about 5 ° C when stored in storage or in hospitals or pharmacies. When stored with the user, they are often stored at room temperature for up to one month. In particular, insulin is stored at room temperature, because the user usually has to carry the insulin with him at all times. The concentration of insulin and preservative should be close to a constant within the storage period. If the concentration of the preservative is too low, the medication will not be sufficiently preserved. It could be suggested to prepare the medication with a higher initial concentration of preservative. This could, however, not be acceptable for parenteral use. The water loss should also be very low during the storage time, because the loss of a very large amount of water could result in a high concentration of active drug and possibly a very high concentration of preservatives. If too much water is lost, the user can overdose on the active medication, such as insulin. In addition, it is important that the user be able to visually inspect the medication to ensure that the drug has not crystallized or polymerized due for example to self-association or denaturation, or that any other visually detectable change in the drug has occurred, such as oxidation of the drug. active medication. The object of the present invention is to provide a container for medicament of a polymeric material, which material is substantially inert to the medicament, and whose container is transparent and provides a good barrier against m-cresol / phenol / benzyl alcohol and water, respectively. Another object of the invention is to provide a container for medicament, which is inexpensive and easy to produce. Still another object of the invention is to provide a container for medicament for the long-term storage of aqueous medicaments, such as aqueous solutions of insulin or human growth hormone. The containers for medicament according to the present invention, for the storage of a liquid medicament comprising one or more active medicaments, water and m-cresol and / or phenol and / or benzyl alcohol, comprise a dist.al end portion and * a proximal end portion and a wall, at least two portions of the wall that are made of a polymeric material. These polymer wall portions have a thickness between 0.3 mm and 3 mm, preferably between 0.5 mm and 1 mm, a light transmission at 400 nm of 25% or more, measured across the opposite wall portions of the container when the vessel is filled with water, using a standard spectrophotometer and air as a reference, and the polymer wall portions are made of a material comprising at least 70% by weight of a copolymer material composed of aliphatic cyclic or bicyclic hydrocarbons with a ring or rings of 5 to 7 members and ethylene or propylene, the material having a vitreous transition temperature higher than 50 ° C, measured by differential scanning calorimetry, when cutting parts of the walls of the container and heating them in an aluminum pan of 10 ° C until 270 ° C at a scanning speed of 10 ° C / min, the glass transition temperature being determined as the temperature at the inflection point, and a density of 0.95 g / cm3 or more. The material can comprise up to 5% by weight of additives, in particular selected from antioxidants, lubricants, such as stearates and silicones, surface active agents, nucleating and clearing agents, and up to 30% by weight of inert fillers, such as Glass particles having a refractive index approximately equal to the refractive index of the polymeric material, the total amount of additives and fillers is up to 30% by weight. As explained above, the dispersion and absorbance of the visible light of the material must be low in order to control the quality of the drug in the container. The quality control can be a visual inspection for foreign particles, homogeneity of a suspension, sedimentation of the crystals, precipitation in solutions, fibrillation or polymerization of peptides or proteins in solutions, and changes in the absorbance spectrum of the drug solution. More critical are the changes that affect the concentration of the active drug or the drug in the solution, and of these, a polymerization or precipitation can be very difficult to observe by a user, especially if the container has a low light transmission . For some insulin formulations, it is important that a diabetic patient can visually observe if more than 3% of the insulin is polymerized. Polymerized insulin can be observed visually and with a spectrophotometer, as a change in the transmission of light. The typical change in transmission from an insulin solution where 3% of the insulin is polymerized, corresponds to the transmission change in the 1: 400 standard of the European Pharmacopoeia and a typical change in the transmission of an insulin solution in where 30% of the insulin is polymerized, corresponds to the change of transmission in 1:40 of the standard of the European Pharmacopoeia (European Pharmacopoeia 1997 section 2.2 Physical and Physicochemical Methods 2.2.1 Clarity and Degree of Opalescence of Liquids). In a glass vessel, the transmission typically changes from about 94% to about 45% with a European Pharmacopoeia standard of 1:40 at 400 nm and a wall thickness of 0.9 mm. In an amorphous cyclic polyolefin, the transmission typically changes from about 85% to about 41% with a European Pharmacopoeia standard of 1:40, changes visually perceived by the eye. In highly transparent polypropylene, the transmission typically changes from about 40% to about 18%. In a less transparent polypropylene, the transmission typically changes from about 15% to about 6%, or even from about 4% to about 3%, all changes being determined, using a 1:40 standard of the European Pharmacopoeia. It is obvious that the patient has the best chance of observing such a problem in a container for medication where the transmission is high, and where the changes are large. In practice, the transmission in a 3 ml container with a wall thickness of 0. 9 mm and filling with a commercial insulin solution, such as Actrapid 100 Ul / l (Novo Nordis A / S), is recommended as being greater than 25% at 400 nm, in order to make it possible to visually observe a greater polymerization of 3%. A few materials for packaging parenteral drugs preserved with m-cresol have surprisingly been found among the group of polyolefin materials. As explained above, any material must meet a number of specifications to be able to prevent m-cresol and water from disappearing from the drug formulation, and be able to allow visual inspection of product quality.

The medicine containers of the present invention should preferably meet the following requirements: The polymer wall portions have an m-cresol permeability of less than 0.0072 g / m2 / 24 hours, measured after a storage period of three months to 37 ° C and 12% relative humidity (RH) by contacting the polymer wall with an aqueous solution of m-cresol at 3 mg / ml, and a water permeability of less than 0.4 g / m2 / 24 hours, measured after from a storage period of three months at 37 ° C and 12% relative humidity, more preferably the polymer wall portions have an m-cresol permeability of less than 0.0055 g / m2 / 24 hours, and even more preferably less than 0.0020 g / m2 / 24 hours, then measured a storage period of three months at 37 ° C and 12% relative humidity, by contacting the polymer wall with an aqueous solution of 3 mg / ml of m-cresol, and preferably the wall portions of the polymer t They have a water permeability of less than 0.35 g / m2 / 24 hours, more preferably less than 0.30 g / m2 / 24 hours, and even more preferably less than 0.20 g / m2 / 24 hours, measured after a storage period of three hours. months at 37 ° C and 12% relative humidity. Preferably, the polymer wall portions having a water permeability of less than 0.025 g / m2 / 24 hours, measured after a storage period of three months at 8 ° C and 13% relative humidity for 36 months, more preferably less than 0.021 g / m2 / 24 hours. The m-cresol, the benzyl alcohol and the phenol are all organic solvents with very low water solubility. M-cresol is less polar than phenol and benzyl alcohol, and therefore will diffuse faster than phenol and benzyl alcohol in a very hydrophobic environment. In addition, the solubility of m-cresol will be greater in a hydrophobic environment such as a cyclic polymer. Even though phenol and benzyl alcohol are smaller molecules than m-cresol and that size may be important for the rate of diffusion, it has been found that the loss of phenol or benzyl alcohol will be smaller than the loss of m-cresol. cresol, and is therefore sufficient to determine the loss of m-cresol. According to the present invention it is even more preferred that the drug container, particularly in parenteral drug applications, meet the following requirements: The water loss must be less than 1.5% after storage at 37 ° C and 12% Relative humidity for three months, and should be less than 1% after storage at 8 ° C and 13% relative humidity for 36 months. For a 3 ml container with an internal diameter of 9.5 mm. this corresponds to a permeability at 37 ° C of approximately 0.35 g / m2 / 24 hours and at 8 ° C of approximately 0.021 g / m2 / 24 hours. The loss of m-cresol should be less than 10% for the entire container, and preferably 7.5% for the polymer wall portions of the container, after storage at 37 ° C and 12% relative humidity for 3 months. For a 3 ml container with an internal diameter of 9.25 mm and a wall thickness of 0.9 mm, this corresponds to a permeability of approximately 0.0053 g / m2 / 24 hours. According to the invention, it has been found that a group of polymeric containers meet the specification, namely the containers comprising amorphous polymers composed of aliphatic, cyclic or bicyclic hydrocarbons, with 5 to 7 members in the ring, and ethylene or propylene, the material having a vitreous transition temperature higher than 50 ° C, measured by differential scanning calorimetry, when cutting parts of the walls of the container and heating them in an aluminum pan from 10 ° C to 270 ° C at a scanning speed of 10 ° C / minute, the glass transition temperature being determined with the temperature at the inflection point; and a density of 0.95 g / cm3 or greater. The amorphous copolymer material is preferably composed of aliphatic cyclic hydrocarbons with 5-7 membered ring and rings and ethylene, and preferably the copolymer material is completely amorphous, that is, it has a crystallinity of less than 1% by weight. More preferably, the amorphous copolymer material is of the type sold under the trade name "Topas", marketed by Schott and Hoechst (see table 1). Also, it is preferred that the amorphous polymer wall portions of the container according to the invention have a light transmission at 400 nm of 60% or greater, and more preferably a light transmission at 400 nm of 75% or more, measured as is specified above.

The density of the amorphous polymer wall portions of the container according to the invention is preferably between 0.95 g / cm.sup.3 and 1. 05 g / cm3, more preferably of approximately 1.02 g / cm3. The vitreous transition temperature (Tg) is preferably at least 75 ° C, and more preferably at least 100 ° C, measured as specified above. Steam sterilization is available for the sterilization of containers that have Tg 's above these temperatures. For polymer containers that have lower Tg's, gamma-ray sterilization is useful. In general, the higher the ratio of cyclic components to the linear components in the copolymer, the higher the Tg of the polymer. The water barrier properties are correlated to the content of the cyclic component in the polymer, since the water barrier is increased by decreasing the amount of the cyclic component relative to the linear component to a certain degree. Preferably, the polymeric material comprises at least 20% linear olefin, preferably at least 50% linear olefin, such as ethylene. Accordingly, the glass transition temperature is preferably at more than 200 ° C, such as at most 170 ° C, more preferably at most 150 ° C. The amorphous polymer preferably comprises at least 75%, more preferably more than 95%, and still more preferably 98% by weight or more of a copolymer material, such as a polyolefin. The remainder of the material may preferably be up to 5% by weight of additives, in particular selected from antioxidants, lubricants, such as stearates and silicones, surface active agents, nucleating and clarifying agents, and inert fillers, such as glass particles. having a refractive index approximately equal to the refractive index of the polymeric material, the total amount of additives and fillers being up to 30% by weight. The container according to the invention having portions of polymeric wall of amorphous polymeric material, can have any suitable shape. It is preferred that the inner surface of the wall, and preferably also the outer surface of the container wall, have a substantially cylindrical shape, because if a flexible rubber piston, a few degrees in the container, is rotated, it can be only maintain its tightening effect if at least the internal surface of the container has a substantially cylindrical shape. The container can preferably be a cartridge, the distal end portion comprises a pierceable seal, and the proximal external portion comprises a plunger. Such cartridges are known in the art. The polymer wall portions preferably constitute at least 30%, preferably more than 50%, and more preferably more than 80% of the area of the wall. The container may have thicker and thinner wall parts. Improved transmission can be obtained by decreasing the thickness of one or more parts of the vessel wall. This will obviously affect the barrier properties in these parts. The improved barrier properties to the container can be obtained by increasing the thickness of one or more parts of the container wall. In a preferred embodiment according to the invention, the container is a cartridge having a polymer wall with an internal cylindrical side, and a distal end portion comprising a pierceable seal, and a proximal end portion comprising a plunger, having the wall a varying thickness to provide a very transparent window. The wall of the container can be processed preferably by injection molding, in particular, if the main part or the entire wall is made of polymeric material. The invention also relates to the use of containers for storing a medicament comprising one or more preservatives. The medicament is preferably an aqueous solution or suspension of human growth hormones, or an aqueous solution or suspension of insulin, preferably comprising between 25 and 600 IU of insulin, between 0.1 and 5 mg of phenol or benzyl alcohol, and between 0.5 and 5 mg of m-cresol per ml of medication.

In the examples, the following methods have been used to determine the properties of the materials: Permeability The materials were molded in 3 ml containers with an outer diameter of 11.05 mm, and internal diameter of 9.25 mm, and thus a wall thickness of 0.90 mm. The containers were closed with a bromobutyl rubber stopper at one end and a natural bromobutyl rubber laminate at the other end. The permeability of m-cresol was measured after storage of the container with insulin (Actrapid, 100 U / ml, Novo Nordisk A / S) at 37 ° C, 13% relative humidity for 3 months. The water permeability was measured after storage of the container with the insulin formulation (Actrapid, 100 U / ml, Novo Nordisk A / S) at 37 ° C, 13% relative humidity for 3 months and at 8 ° C, 13% of relative humidity for 6, 12 and 18 months.

Permeability of m-cresol The loss of m-cresol was measured after a storage period of three months at 37 ° C, with a size exclusion HPLC method using isocratic elution with a mobile phase, on a Protein-Pak 1-125 aters column, with the following composition: 600 g of glacial acetic acid, 600 g of acetonitrile, 2.8 g of L-arginine and water added up to 4000 g. Frozen standards were used to correct the displacement of the HPLC system. The glass containers with the same dimensions as the plastic containers were used to correct the losses through the rubber stopper and the rubber closure. Permeability was calculated.

Water permeability The water permeability was measured as a weight loss after the 3, 6 and 18 month trial period. The loss was linear with time in the trial period, and the results can therefore be extrapolated up to 36 months at 8 ° C. Glass containers with the same dimensions were used as reference.

Transmission The transmission was measured with a standard spectrophotometer, using air as a reference. The container was placed with the light beam perpendicular to the plastic surface, so that the light beam passed through the wall of the container, through the aqueous solution or water contained therein, and out through from the opposite wall of the container to the detector. In this setting, the light passes through the double wall thickness. The diameter of the light beam was kept small, in comparison with the diameter of the container, to avoid reflection on the surface of the container.

Density The densities of the plastics materials were determined by measuring the volumetric change of an aqueous solution, which contained a detergent, when adding a known weight of the plastic to the liquid.

Ethylene content The ethylene content can be measured using proton nuclear magnetic resonance (NMR).

Temperature, glass transition The vitreous transition temperature of the cyclic polyolefin materials was evaluated by DSC differential scanning calorimetry. The samples were cut from the containers and placed in aluminum pans. The samples were subsequently heated from 10 ° C to 270 ° C at a scanning speed of 10 ° C / min. The vitreous transition temperature was evaluated as the temperature at the inflection point on the plateau in the thermal flux that was associated with the glass transition temperature of the material. materials In the examples, the materials in Table 1 were used.

Table 1 Used materials Cyclic Olefins Distributor Development Sample Used in (Yes / No) Example No. Schott Hoechst, Denmark No Topas® 8007 Schott Schott, Denmark No Topas® 5013 Schott Schott, Denmark Yes Topas® 6013 Schott Hoechst, Denmark No Topas® 6015 Schott Hoechst, Denmark No Topas® 6017 Daikyo Schott, Denmark Yes Resin CZ The development materials were received from the companies as: transparent materials not commercially available, under development for later introduction in the market. The development materials are therefore not commercially available as such, but can be obtained from the distributor upon request.

Example 1 Containers of 4 different cyclic polyolefins were produced (see table 1) by injection molding. The 3 ml containers had all outer diameters of 11.05 mm, internal diameters of 9.25 mm, and thus a wall thickness of 0.90 mm. The containers were closed with a bromobutyl rubber stopper at one end, and a bromobutyl / natural rubber laminate at the other end. The Topas materials produced by Hoechst consist of bicyclic monomer elements in combination with ethylene elements and the Cik resin of Daikyo is constituted by monocyclic monomeric elements. The water permeability in the materials was measured at 3 different conditions. The permeability of m-cresol was measured at 37 ° C. The approximate ethylene content was supplied by the manufacturer. The vitreous transition temperature (Tg) was measured with DSC. The permeability data at 25 ° C for Topas 6015 and 6015 are estimated from the manufacturing data and marked with "* w.

Table 2 As can be seen in table 2, the Topas® 8007, Topas® 5013 and Topas® 6013 containers are all excellent with regard to transmission and barrier properties.

The Topas® 8007 sample, which has a vitreous transition temperature of 76 ° C, has a slightly lower permeability than the Tops® 5013 and Topas® 6013 samples, having a higher vitreous transition temperature of 137 and 143 ° C, respectively. The CZ resin is studied as a comparison, the ethylene content of the CZ resin is 0, whereby the cyclic component constitutes 100% of the polymer. The high content of the cyclic component deteriorates the permeability to water, at all temperatures tested, especially at 8 ° C. Also the barrier properties of m-cresol are reduced compared to the polymers according to the invention.

It is noted that in relation to this date, the best method known by the applicant to carry out the aforementioned invention, is the conventional one for the manufacture of the objects to which it relates.

Claims (22)

CLAIMS Having described the invention as above, the content of the following claims is claimed as property:

1. A container for medicament for storing a liquid medicament comprising one or more medicaments, water and m-cresol and / or phenol and / or benzyl alcohol, the container is characterized in that it comprises a distal end portion and a proximal end portion and a wall, at least two opposite portions of the wall that are made of a polymeric material, the polymer wall portions have a thickness between 0.3 mm and 3 mm, a light transmission at 400 nm of 25% or greater, measured through both opposite wall portions of the container when the container is filled with water, using a standard spectrophotometer and air as reference, the polymer wall portions being a material comprising at least 70% by weight of an amorphous copolymer material composed of cyclic hydrocarbons or bicyclics with ring or rings of 5 to 7 members and ethylene or propylene, the material having a glass transition temperature greater than 50 ° C, measured differential scanning calorimetry, by cutting pieces from the walls of the container and heating them in an aluminum pan from 10 ° C to 270 ° C at a scanning temperature of 10 ° C / min, the glass transition temperature being determined as the temperature at the point of inflection; and a density of 0.95 g / cm3 or greater.

2. A container according to claim 1, characterized in that the polymeric wall material comprises at least 75%, preferably more than 95%, and more preferably more than 98% by weight of the copolymer material.

3. A container according to claim 1 or 2, characterized in that the polymeric wall material comprises up to 5% by weight of additives, preferably from antioxidants, lubricants, surface active agents, nucleating and clarifying agents, and even 30% by weight of inert fillers, preferably glass particles having a refractive index approximately equal to the refractive index of the polymeric material, the total amount of additives and fillers being up to 30% by weight.

4. A container according to any of claims 1, 2 or 3, characterized in that the copolymer material is composed of cyclic ring of 5-7 members, preferably bicyclic, and ethylene.

5. A container according to any of claims 1 to 4, characterized in that the polymeric material comprises at least 20% ethylene, preferably at least 50% ethylene.

6. A container according to any of claims 1 to 5, characterized in that the copolymer material is completely amorphous.

7. A container according to any of claims 1 to 6, characterized in that the amorphous polymer wall portions have a light transmission at 400 nm of 60% or more, preferably a light transmission at 400 nm of 75% or more. more, measure as defined in claim 1.

8. A container according to any of claims 1 to 7, characterized in that the amorphous polymer wall material has a density between 0.95 g / cm3 and 1.05 g / cm3, preferably about 1.02 g / cm3.

9. A container according to any of claims 1 to 8, characterized in that the polymeric wall material has a glass transition temperature of at least 75 ° C, preferably at least 100 ° C.

10. A container according to any of claims 1 to 9, characterized in that the polymeric wall material has a glass transition temperature of at most 200 ° C, preferably at most 170 ° C, more preferably at most 150 ° C. C.

11. A container according to any of claims 1 to 10, characterized in that the container wall has an internal surface and an external surface, the internal surface has a substantially cylindrical shape.

12. A container according to any of claims 1 to 11, characterized in that the container wall has an internal surface and an external surface, the external surface of the wall has a substantially cylindrical shape.

13. A container according to any of claims 1 to 12, characterized in that the container is a cartridge, the distal end portion thereof comprises a pierceable seal and a proximal end portion comprising a plunger.

14. A container according to any of claims 1 to 13, characterized in that the polymer wall portions constitute at least 30%, preferably more than 50%, and more preferably more than 80% of the area of the wall.

15. A container according to any of claims 1 to 14, characterized in that the polymer wall portions have an m-cresol permeability of less than 0.0072 g / m2 / 24 hours, measured after a storage period of three months to 37 ° C and 12% relative humidity, by contacting the polymer wall with an aqueous solution of m-cresol at 3 mg / ml, and a water permeability of less than 0.4 g / m2 / 24 hours, measured after a storage period of three months at 37 ° C and 12% relative humidity.

16. A container according to claim 15, characterized in that the polymer wall portions have an m-cresol permeability of less than 0.0070 g / m2 / 24 hours, preferably less than 0.0055 g / m2 / 24 hours, and more preferably less than 0.0020 g / m2 / 24 hours, measured after a storage period of three months at 37 ° C and 12% relative humidity, by contacting the polymer wall with an aqueous solution of m-cresol at 3 mg / ml.

17. A container according to claim 15 or 16, characterized in that the polymer wall portions have a water permeability of less than 0.35 g / m2 / 24 hours, preferably less than 0.30 g / m2 / 24 hours, and more preferably less than 0.20 g / m2 / 24 hours, measured after a storage period of three months at 37 ° C and 12% relative humidity.

18. A container according to claim 15, 16 or 17, characterized in that the polymer wall portions have a water permeability of less than 0.025 g / m2 / 24 hours, preferably less than 0.021 g / m2 / 24 hours, measured after a storage period of 36 months at 8 ° C and 13% relative humidity.

19. The use of a container for medication according to any of claims 1 to 18, for the storage of a medicament comprising one or more preservatives.

20. The use according to claim 19, wherein the medicament is an aqueous solution of insulin or aqueous suspension of insulin, preferably comprising between 25 and 600 U of insulin, between 0.1 and 5 mg of phenol and / or benzyl alcohol, and between 0.5 and 5 mg of m-cresol per ml of medication.

21. The use according to claim 19, wherein the medicament is an aqueous solution or suspension of the human growth hormone.

22. A container for medicament according to any of claims 1 to 18, characterized in that it is at least partially filled with a solution of liquid medicament, comprising one or more active medicaments, water and m-cresol and / or phenol and / or benzyl alcohol. SUMMARY OF THE INVENTION The present invention relates to a container for medicament, for storing a liquid medicament, such as insulin, the container comprising a distal end and a proximal end and a wall, at least two opposite portions of the wall that are made of a polymeric material. The thickness of the portions of the polymer wall is between 0.3 mm and 3 mm, and the transmission of light through the polymer wall portions at 400 nm is at least 25%. The polymer wall portions are made of a material comprising at least 70% by weight of a copolymer material composed of aliphatic cyclic or bicyclic hydrocarbons with 5 to 7 membered ring or rings and ethylene or propylene, the material having a vitreous transition temperature greater than 50 ° C, and a density of 0.95 g / cm2 or greater. The container of polymeric material is substantially inert to the medicament, and in addition, the container is transparent, whereby it is possible to visually inspect the contents of the container to ensure that the medicament is not crystallized or polymerized. In addition, the walls of the container provide a good barrier against the preservatives of m-cresol / phenol / benzyl alcohol and water, respectively. The invention also relates to the use of such a container for medicament, and a container for medicament at least partially filled with medicament.